HSA
SAGE

Hussman Strategic Advisors’s Sage Therapeutics SAGE Stock Holding History

Hussman Strategic Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,400
Closed -$255K – 290
2023
Q3 		$255K Hold
12,400
– – 0.05% 262
2023
Q2 		$583K Sell
12,400
-13,600
-52% -$677K 0.11% 243
2023
Q1 		$1.09M Hold
26,000
– – 0.17% 208
2022
Q4 		$992K Hold
26,000
– – 0.16% 206
2022
Q3 		$1.02M Hold
26,000
– – 0.18% 201
2022
Q2 		$840K Hold
26,000
– – 0.14% 221
2022
Q1 		$861K Hold
26,000
– – 0.17% 196
2021
Q4 		$1.11M Sell
26,000
-48,400
-65% -$2.03M 0.24% 142
2021
Q3 		$3.3M Hold
74,400
– – 0.73% 23
2021
Q2 		$4.23M Buy
+74,400
New +$5.26M 0.88% 6

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's SAGE Position: Q4 2023 in Review

Hussman Strategic Advisors sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 12,400 shares — an estimated $255K sold.

Hussman Strategic Advisors first reported a position in SAGE in Q2 2021 and held it in 10 quarters. The position peaked at $4.23M in Q2 2021. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

  • Hussman Strategic Advisors reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Hussman Strategic Advisors sold 12,400 Sage Therapeutics shares in Q4 2023, an estimated $255K.
  • Hussman Strategic Advisors first reported a position in Sage Therapeutics in Q2 2021 and held it in 10 quarters.
  • Hussman Strategic Advisors's Sage Therapeutics position peaked at $4.23M in Q2 2021.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on Hussman Strategic Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.